Abstract
Purpose: To evaluate the efficacy and safety of subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture in recurred pterygium.Methods: We retrospectively reviewed the medical records of 9 patients (11 eyes) who received subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture for recurred pterygium. All patients included in this study completed follow-up for at least 12 months. Demographic variables, postoperative clinical outcomes, and recurrence rate were analyzed. Recurrence of pterygium was evaluated at 12 months after surgery.Results: The study subjects comprised 5 male patients (5 eyes) and 4 female patients (6 eyes) with a mean age of 66.0 ± 13.0 years (range 43-78 years). Among the 11 eyes, no recurrence occurred after the follow-up period of 12 months.Conclusions: Subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture appears to be an effective method of preventing the recurrence in recurred pterygium.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
